Welcome to Markets Desk, here's what's moving the needle right now.
Eli Lilly is having a standout session after the company showed what demand actually looks like when price stops being the obstacle. More than five hundred thousand Medicare enrollees have signed onto a pilot program offering obesity drugs at fifty dollars a month, and the market is reading that as a structural demand unlock, not a one-time pop. The stock surged on the news.
Shifting to geopolitics with a direct commodity angle, Ukraine's sustained drone campaign against Russia's shadow oil fleet is forcing Moscow into increasingly improvised defenses, with vessels now reportedly deploying fishing nets and rubber tires as makeshift armor. Oil exports remain a primary funding mechanism for Russia's war effort, and any sustained disruption to that fleet tightens the supply picture in ways traders are watching closely.
Meanwhile, the Anthropic IPO is generating real positioning ahead of its arrival, and Broadcom is emerging as the clearest public-market beneficiary. The chipmaker holds a multi-year infrastructure agreement with Anthropic worth tens of billions of dollars, giving investors an existing equity handle on what is otherwise a private-market story for now.
That's the tape. Markets Desk, signing off the floor.
